The One Number That Matters to BlackBerry from the Microsoft/Nokia Deal

The reaction that BlackBerry’s stock has had to the MSFT/NOK deal has this Fool scratching his head.

| More on:
The Motley Fool


This is the price/revenue figure that Bloomberg reported Microsoft (NASDAQ:MSFT) is paying to buyout Nokia’s (NYSE:NOK) handset unit and license its patent portfolio.

Handset unit?  Patent portfolio?  Both of these items sound very familiar to those of us following the BlackBerry (TSX:BB, NASDAQ:BBRY) story.

Not only does Microsoft buying Nokia potentially take a buyer off the table as BlackBerry continues to shop itself.  It also potentially draws a line in the sand as to what price a buyer might be willing to pay.

For those of you hanging on to BlackBerry shares hoping for it to pop if/when a buyer is found, this number is not a favourable one.

With total revenues over the past 12 months of $11.3 billion, and a current market capitalization of $5.7 billion, BlackBerry currently trades at a price/revenue multiple of 0.50.  BlackBerry shares would have to be trading right around $7.50 to carry a multiple of 0.35.  That’s about 30% lower than where they currently sit.

The Foolish Bottom Line

Though BlackBerry’s shares are seemingly up on the day because of this MSFT/NOK news, it’s not entirely clear why this is so.  One less buyer and a valuation precedent that is lower than where the company currently trades doesn’t seem like positive news to this Fool.

Not all Canadian companies are as volatile as BlackBerry.  For a profile of some of the best this country has to offer click here now and download our special FREE report “5 Stocks to Replace Your Canadian Index Fund”.  One of the 5 just got taken out a huge premium.  Click here now to learn about the other 4, at no charge!

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.

Follow us on Twitter and Facebook for the latest in Foolish investing.

Fool contributor Iain Butler doesn’t own shares of any companies mentioned.  The Motley Fool owns shares of Microsoft.    

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing

Stock analysts were once excited about construction company Aecon as an investment.

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Specialty Brands faces higher raw materials costs.
Dividend Stocks

What’s Next for Premium Brands Stock?

Shares of the specialty food production and distribution company have fallen about 25% since last October.

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Dividend Stocks

2 Interesting Buys in Any Market

Here are two intriguing buys in any market climate that offer defensive appeal as well as growth and income earning…

Read more »

Bank sign on traditional europe building facade
Bank Stocks

Should You Buy Bank Stocks Now?

Canadian bank stocks are getting cheap. Is this the right time to buy?

Read more »

stock data
Stocks for Beginners

2 Reliable Stocks Beginners Can Buy Amid the Market Selloff

As the broader market turmoil continues, new investors can buy these two reliable dividend stocks to get good returns on…

Read more »

Biotech stocks can be good yet risky investments.

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »

Dividend Stocks

TFSA Investors: 3 TSX Stocks for Tax-Free Passive Income

These Canadian corporations have strong visibility over future earnings and dividend payouts.

Read more »

Piggy bank next to a financial report

Do You Have Cash Sitting in Your TFSA? Now Is a Great Time to Buy Stocks

If you have cash in your TFSA that you're looking to invest, now is a great time to buy high-quality…

Read more »